MRT
Marti Technologies, Inc.·Technology
2.04
0.000%(+0.00)
Market ClosedLast Updated: — ET
52W L: $1.9752W H: $3.70
MRT NEWS
businesswire.com
1d ago
Marti Technologies, Inc. to Report 2025 Fiscal Year Results on April 13, 2026
ISTANBUL--(BUSINESS WIRE)--Marti Technologies, Inc. (“Marti”) (NYSE American: MRT), Türkiye's leading mobility super app, will announce its financial and operational results for the fiscal year ended December 31, 2025 (“2025 Fiscal Year Results”) before the U.S. markets open on Monday, April 13, 2026. Conference Call and Webcast Details Marti's management will host an analyst and investor conference call and live webcast to discuss its 2025 Fiscal Year Results at 3:30 p.m. Istanbul / 1:30 p.m.
businesswire.com
Mar 18
Marti's Ride-Hailing Service Reaches 3.80 Million Riders and 490 Thousand Registered Drivers, Exceeding March 31, 2026 Targets
ISTANBUL--(BUSINESS WIRE)--Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT), Türkiye's leading mobility super app, announced today that as of March 17, 2026, Marti's ride-hailing service has reached 3.80 million riders and 490 thousand registered drivers, exceeding the March 31, 2026 targets of 3.80 million riders and 485 thousand registered drivers. Marti's number of ride-hailing riders grew 101% from March 17, 2025 to March 17, 2026. The number of registered drivers gr.
globenewswire.com
Mar 17
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated in H2 2026 Newly announced unblinded safety data from MRT-8102 SAD/MAD cohorts continue to support favorable safety/tolerability profile and wide therapeutic window Company plans to initiate multiple Phase 2 studies of MRT-8102, including in patients with elevated CVD-risk in H2 2026, in patients with gout flares in Q4 2026/Q1 2027, and in patients with moderate to severe hidradenitis suppurativa in H1 2027 Presented positive interim data from the Phase 1/2 clinical study of MRT-2359 in combination with enzalutamide showing 100% PSA response rate in metastatic castration-resistant prostate cancer (mCRPC) patients with AR mutations Phase 2 study initiation of MRT-2359 in combination with apalutamide in mCRPC patients with AR mutations anticipated in Q3 2026 VAV1-directed MGD MRT-6160 advancing toward anticipated initiation by Novartis of multiple Phase 2 studies in immune-mediated diseases $345 million upsized follow-on financing further strengthens balance sheet, supporting operations into 2029 and through multiple anticipated Phase 2 study initiations and clinical data readouts BOSTON, March 17, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2025. “Monte Rosa is now on the cusp of Phase 2 trial initiations for three clinical-stage programs, each targeting expansive opportunities.
globenewswire.com
Mar 16
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment
businesswire.com
Mar 9
Marti Launches Shareholder Loyalty Program
ISTANBUL--(BUSINESS WIRE)--Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT), Türkiye's leading mobility super app, today announced the launch of the Marti Shareholder Loyalty Program, a new initiative designed to reward long-term retail shareholders while reinforcing Marti's commitment to sustainable growth, stakeholder alignment, and responsible value creation. The Marti Shareholder Loyalty Program provides verified retail shareholders with exclusive benefits directly c.
globenewswire.com
Feb 24
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, including 2 patients with RECIST partial responses and 3 with stable disease, all showing reduction in size of target lesions Across all 15 evaluable patients, the overall RECIST disease control rate was 67%, and 10 of 15 patients showed tumor size reductions of target lesions Combination of MRT-2359 and enzalutamide was generally well-tolerated with primarily Grade 1-2 adverse events (AEs); no treatment discontinuations due to AEs Company plans to initiate a new, signal-confirming Phase 2 study of MRT-2359 targeting AR mutant patients in Q3 2026 Poster presentation on February 26 at 11:30 AM PST BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced updated, positive clinical data from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC). The data, being presented at the 2026 ASCO GU Symposium in San Francisco, CA, build on data released by the company in December 2025.
